Vit Kit® - Freeze (Vitrification Freeze Kit) is intended for use in the vitrification of oocytes (MI), pronuclear (PN) zygotes through day 3 cleavage stage embryos and blastocyst stage embryos.

Vit Kit® - Thaw (Vitrification Thaw Kit) is intended for use in the thawing of vitrified oocytes (MI), pronuclear (PN) zygotes through day 3 cleavage stage embryos and blastocyst stage embryos.

Device Description

The five media that comprise the two kits, Vit Kit® - Freeze and the Vit Kit® - Thaw are all based upon a modified formulation of Medium 199 is HEPES buffered and contains 20% (v/v) dextran substitute supplement (DSS), 35μ.g/mL gentamicin and varying concentrations of dimethyl sulfoxide (DMSO), ethylene glycol (EG), and sucrose. The two freeze media in the Vit Kit® - Freeze are intended to be used sequentially, for the preparation and cryopreservation of PN, day 3 cleavage stage, and blastocyst stage embryos and oocytes.

The three thaw media in the Vit Kit®- Thaw are intended for sequential use in the thawing and recovery of cryopreserved human PN, cleavage stage, and blastocyst embryos and oocytes.

AI/ML Overview

The provided text describes the acceptance criteria and a clinical study conducted for the Vit Kit® - Freeze and Vit Kit® - Thaw products, specifically to support the expanded indication for use to include oocytes (MII).

Here's an analysis of the provided information to address your request:

1. A table of acceptance criteria and the reported device performance

The document presents product specifications that act as acceptance criteria for the manufacturing release of the media, and then discusses clinical performance.

Product Specifications (Acceptance Criteria & Reported Performance):

Final Product Test Specification	Vit Kit® - Freeze (K093273 & K160006)	Vit Kit® - Thaw (K093273 & K160006)
	ES Freeze 90131	VS Freeze 90132
Appearance	Pass	Pass
pH	7.05 - 7.54	7.05 - 7.54
Osmolality (mOsm/KgH2O)	1,055 – 1,445	1,100 - 1,588
Endotoxin (EU/mL)	0.03 - 0.60	0.03 - 0.60
Sterility	Pass	Pass
Modified Mouse Embryo Assay (% of Control)	80 - 100	80 - 100
Albumin Recovery (%)	85 - 200	85 - 200

Note: The table above reflects the identical specifications for both the predicate and proposed device, implying these are the acceptance criteria that the device meets "prior to their release for sale." The document states "Results of all release assays performed are reported on a lot-specific certificate of analysis, and are indicated on the labeling," confirming they meet these criteria.

Clinical Performance (Acceptance Criteria & Reported Performance for Oocyte Vitrification):

The clinical study aimed to demonstrate comparability between frozen oocyte transfers (using the Vit Kit) and fresh oocyte transfers. The implicit acceptance criteria are that the performance metrics for frozen oocytes are acceptable and comparable to fresh oocytes, and generally align with established ART success rates.

Clinical Performance Metric	Fresh Oocytes (Reported Performance)	Frozen Oocytes (Reported Performance)	Acceptance Criteria (Implicit)
% Fertilized	(Baseline, numerical value not given, but implied higher than frozen)	15% lower than fresh oocytes	Acceptable, as it "did not impact the % Implantation Rate/Transfer and % Pregnancy Rate/Transfer"
% Implantation Rate/Transfer	(Baseline)	Comparable to fresh oocytes	Comparable to fresh oocytes
% Pregnancy Rate/Transfer	(Baseline)	Comparable to fresh oocytes	Comparable to fresh oocytes
% Live Births/Transfer	Lower than frozen oocytes in study; Comparable to CDC 2013 data	Higher than fresh oocytes in study; Similar to CDC 2013 data	Acceptable and/or similar/higher than fresh oocytes and/or CDC data
% Live Births/Pregnancy	Comparable to CDC 2013 data	Significantly higher than CDC 2013 data	Acceptable and/or similar/higher than fresh oocytes and/or CDC data

2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

Test Set Sample Size: "up to 400 patients" volunteered.
Data Provenance:
- Type: Prospective, multicenter clinical study.
- Country of Origin: Not explicitly stated, but given FDA submission, it's highly likely to be primarily US-based, potentially with international centers typical for multicenter studies. However, this is an inference, not directly stated.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)

This study is a clinical trial involving patients and the outcomes of IVF procedures (fertilization, implantation, pregnancy, live birth). The "ground truth" for these metrics (e.g., successful fertilization, confirmed pregnancy, live birth) is established through standard medical procedures and clinical observation, not through expert consensus on image review or similar subjective assessments. Therefore, the concept of "experts establishing ground truth for the test set" in the context of radiologists or similar is not directly applicable here. The outcomes are objective clinical endpoints.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

Not applicable. This is a clinical trial assessing device performance on biological samples and patient outcomes, not an imaging study requiring expert adjudication of interpretations. The clinical outcomes are observed and recorded.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This is not an AI/imaging study, but rather a study of a medical device (vitrification media) and its clinical effectiveness. No human "readers" or AI assistance are involved in the assessment of the outcomes.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

Not applicable. This is not an algorithm-based device. The "performance" is the efficacy of the media in cryopreservation and its impact on subsequent clinical outcomes.

7. The type of ground truth used (expert concensus, pathology, outcomes data, etc.)

The ground truth is outcomes data directly observed in human patients undergoing IVF:

Fertilization rates
Implantation rates
Pregnancy rates
Live birth rates

8. The sample size for the training set

Not applicable. This is a medical device (chemical media), not an algorithmic or AI model. Therefore, there is no "training set."

9. How the ground truth for the training set was established

Not applicable, as there is no training set for this type of device. The product formulation is based on scientific principles of cryopreservation. The product's consistent performance is validated through non-clinical assays (Part 1, Table 1) and clinical performance (Part 1, Table 2).

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus symbol, which is a staff with two snakes coiled around it. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the caduceus symbol. The logo is black and white.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

May 4, 2016

Irvine Scientific Jayme Yamaguchi-Owens Regulatory Affairs Manager 2511 Daimler St Santa Ana, CA 92705

Re: K160006

Trade/Device Name: Vit Kit-freeze Oocytes, Embryos and PN Zygotes Vitrification Freeze Kit. Vit Kit-thaw Oocytes, Embryos and PN Zygotes Vitrification Thaw Kit Regulation Number: 21 CFR 884.6180 Regulation Name: Reproductive Media and Supplements Regulatory Class: Class II Product Code: MQL Dated: April 1, 2016 Received: April 5, 2016

Dear Jayme Yamaguchi-Owens,

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply

{1}------------------------------------------------

with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Herbert P. Lerner -S

Benjamin R. Fisher, Ph.D. for Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K160006

Device Name

Vit Kit® - Freeze (Vitrification Freeze Kit)

Indications for Use (Describe)

Vit Kit® - Freeze (Vitrification Freeze Kit) is intended for use in the vitrification of oocytes (MI), pronuclear (PN) zygotes through day 3 cleavage stage embryos and blastocyst stage embryos.

Type of Use (Select one or both, as applicable)
-------------------------------------------------	--

X Prescription Use (Part 21 CFR 801 Subpart D)

| Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Indications for Use

510(k) Number (if known) K160006

Device Name Vit Kit® - Thaw (Vitrification Thaw Kit)

Indications for Use (Describe)

Vit Kit® - Thaw (Vitrification Thaw Kit) is intended for use in the thawing of vitrified oocytes (MI), pronuclear (PN) zygotes through day 3 cleavage stage embryos and blastocyst stage embryos.

Type of Use (Select one or both, as applicable)
-------------------------------------------------

X Prescription Use (Part 21 CFR 801 Subpart D)

| Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{4}------------------------------------------------

510(k) SUMMARY AS REQUIRED BY SECTION § 807.92(c)

Submitters Name and Address:	Irvine Scientific Sales Co., Inc.2511 Daimler StreetSanta Ana, CA 92705Telephone: 800-437-5706Facsimile: 949-261-6522
Manufacturing Site:	2511 Daimler StreetSanta Ana, CA 92705
Contact Person:	Jayme Yamaguchi-OwensIrvine Scientific Sales Co., Inc.2511 Daimler StreetSanta Ana, CA 92705Telephone: 800-437-5706Facsimile: 949-261-6522Email: jfy@irvinesci.com
Date Prepared:	May 4, 2016
Establishment Registration Number:	2022379
510(k):	K160006
Trade or Proprietary Name:	Vit Kit® - FreezeOocytes, Embryos and PN zygotesVitrification Freeze Kit
	Vit Kit® - ThawOocytes, Embryos and PN zygotesVitrification Thaw Kit
Common Name:	Vitrification Freezing and Thawing Kits
Device Regulation:	21 CFR § 884.6180
Device Classification:	Class II
Product Code:	MQL
Predicate Device:	Vit Kit® - Freeze, Irvine Scientific (K093273)Vit Kit® - Thaw, Irvine Scientific (K093273)

{5}------------------------------------------------

Device Description:

The three thaw media in the Vit Kit®- Thaw are intended for sequential use in the thawing and recovery of cryopreserved human PN, cleavage stage, and blastocyst embryos and oocytes.

Indications for Use:

Vit Kit® - Freeze (Vitrification Freeze Kit) is intended for use in the vitrification of oocytes (MII), pronuclear (PN) zygotes through day 3 cleavage stage embryos and blastocyst stage embryos.

Vit Kit® - Thaw (Vitrification Thaw Kit) is intended for use in the thawing of oocytes (MII), pronuclear (PN) zygotes through day 3 cleavage stage embryos and blastocyst stage embryos.

Vit Kit® - Freeze and Vit Kit® - Thaw was previously cleared under K093273 with the intended use for vitrification of pronuclear (PN) through day 3 cleavage stage embryos and blastocyst stage embryos and thawing/warming of vitrified PN through day 3 cleavage stage embryos and blastocyst stage embryos respectively.

The purpose of this submission is to expand the indication for use of the cleared Vit Kit® - Freeze and Vit Kit® - Thaw (K093273) to include oocytes (MII).

The expansion of the indication for use statement to include oocytes in the current submission does not alter the intended use and therapeutic effect of the device (cryopreservation of extra embryos/gametes for use at a later time).

{6}------------------------------------------------

Comparison of Technological Characteristics with the Predicate Device:

The media in the Vit Kit® - Freeze and Vit Kit® - Thaw are designed to be used sequentially for the vitrification and thawing of MII oocytes. PN zygotes, day 3 cleavage stage and blastocyst stage embryos for cryopreservation during assisted reproduction procedures. None of the media are intended to contact the patient.

The composition of the media that comprise the predicate device Vit Kit® - Freeze and Vit Kit® - Thaw (K093273) and the proposed device, Vit Kit® - Freeze and Vit Kit® -Thaw (K160006) are identical as presented in the tables below:

Vitrification Kits
	Cryoprotectant			Media Components
Device	EthyleneGlycol1		Sucrose2	M199		Gentamicin
		DMSO7		AminoAcids	NEAA3	n	Protein
Vit Kit® -Freeze(K093273)	+	+	+	+	+	+	+
Vit Kit® -Freeze(K160006)	+	+	+	+	+	+	+

Table 1: Vitrification Freeze Kit Component Comparison

1 Used at two (2) concentrations, 7.5% (v/v) in the Equilibration Solution and 15% (v/v) in the Vitrification Solution

2 Used at one (1) concentrations, 0.5M in the Vitrification Solution

3 NEAA – non-essential amino acids

{7}------------------------------------------------

Vitrification Warm/Thaw/Warming Kits
Device	Sucrose4	M199		Gentamicin	Protein
		Amino Acids	NEAA
Vit Kit® - Thaw(K093273)	+	+	+	+	+
Vit Kit® - Thaw(K160006)	+	+	+	+	+

Table 2: Vitrification Thaw Kit Component Comparison

The product specifications for the Vit Kit® - Freeze and Vit Kit® - Thaw are identical to the predicate device, as described in the table below:

Final Product TestSpecification	Vit Kit® - FreezeK093273 K160006		Vit Kit® - ThawK093273 K160006
	ESFreeze90131	VSFreeze90132	TSThaw90134	DSThaw90135	WSThaw90136
Appearance	Pass	Pass	Pass	Pass	Pass
pH	7.05 - 7.54	7.05 - 7.54	7.05 - 7.44	7.05 - 7.44	7.05 - 7.44
Osmolality(mOsm/KgH2O)	1,055 –1,445	1,100 -1,588	1,732 -1,912	857 – 910	268 – 292
Endotoxin (EU/mL)	0.03 - 0.60	0.03 - 0.60	0.03 -0.60	0.03 -0.60	0.03 -0.60
Sterility	Pass	Pass	Pass	Pass	Pass
Modified MouseEmbryo Assay (% ofControl)	80 - 100	80 - 100	80 - 100	80 - 100	80 - 100

Table 1: Vit Kit® - Freeze Kit and Vit Kit® - Thaw Product Specifications

4 Sucrose = a non-permeating cryoprotectant used at two (2) concentrations, 1.0M in the Thawing Solution, 0.5M in the Dilution Solution.

{8}------------------------------------------------

Final Product TestSpecification	Vit Kit® - FreezeK093273 K160006		Vit Kit® - ThawK093273 K160006
	ESFreeze90131	VSFreeze90132	TSThaw90134	DSThaw90135	WSThaw90136
Albumin Recovery (%)	85 - 200	85 - 200	85 - 200	85 - 200	85 - 200

The technological characteristics of the Vit Kit® - Freeze and Vit Kit® - Thaw Kit are comparable to the predicate device, do not impact substantial equivalence, and do not raise new issues regarding safety or effectiveness.

Non-clinical Performance Data:

Vit Kit® - Freeze and Vit Kit® - Thaw media are tested using the one cell mouse embryo assay prior to their release for sale. This assay assures that the product is both functional for its intended use, the support of embryonic growth, and that no toxic components are present in the formulation.

Endotoxin, albumin recovery assay, pH, osmolality, appearance and sterility testing are also performed as a condition of release for Vit Kit® - Freeze and Vit Kit® - Thaw media. Results of all release assays performed are reported on a lot-specific certificate of analysis, and are indicated on the labeling.

In addition, shelf-life testing has been performed to ensure no loss of functionality or sterility at the end of the proposed shelf-life.

Clinical Performance Data:

To support substantial equivalence, a clinical study was performed to assess the clinical efficacy of oocyte cryopreservation using the Vit Kit® - Freeze and Vit Kit® - Thaw as compared to non-cryopreserved (fresh) oocytes.

The study was a prospective, multicenter study comprised of up to 400 patients. Inclusion criteria encompassed some of the following: Infertile women < 37 years of age in good general physical and mental health and a normal BMI (≤ 27); Voluntarily wishing to conceive or preserve fertility potential with excess MII oocytes remaining

{9}------------------------------------------------

after a fresh IVF treatment cycle with a minimum of six (6) freezable MII oocytes required with fertilization of oocytes by ICSI only. Exclusion criteria included some of the following: Couples for whom the male partner requires testicular or epididymal sperm retrieval; Uncorrected hydrosalpinx or abnormal uterine cavity; History of hyporesponsiveness or ovarian stimulation or complications related to tolerance to OCP's, Gonadotropins, Progesterone or estrogen or a medical condition that is contraindicated to pregnancy or gonadotropin therapy (examples: allergies, immune deficiency, etc.).

The clinical data demonstrated the comparability between the frozen oocyte and fresh oocyte transfers with regards to the following criteria:

% Implantation Rate/Transfer
. % Pregnancy Rate/Transfer

The % fertilized was observed to be 15% lower for frozen oocytes when compared to fresh oocytes; however, it did not impact the % Implantation Rate/Transfer and % Pregnancy Rate/Transfer, which were comparable to fresh oocytes. The % Live Births/Transfer and % Live Births/Pregnancy were higher for the frozen oocytes when compared to fresh oocytes. Based upon the clinical date, the safety and the effectiveness of the Vit Kit® - Freeze and Vit Kit® - Thaw were demonstrated.

In addition, the clinical data was compared to the current National Assisted Reproductive Technology (ART) Success Rates published in the Centers for Disease Control and Prevention Report of 2013 National Summary in August 2015. This comparison revealed that for the fresh oocytes, the % Live Births/Transfer rates from the clinical study were lower, and the % Live Births/Pregnancy rates were comparable to the CDC data. For frozen oocytes, the % Live Births/Transfer rates were similar and the % Live Births/Pregnancy rates were significantly higher in the clinical study when compared to the CDC data.

Finally, peer-reviewed published literature was provided to support the expansion of the Indications for Use to include oocyte vitrification. Several of these publications provided

{10}------------------------------------------------

clinical data of oocyte vitrification using the subject device. The other published literature included studies that were performed using identical cryoprotectants (ethylene glycol, DMSO, and sucrose) at the same or similar concentrations to those used in the subject device. The clinical study data was compared to the published literature with regards to the number of patients participating, oocyte survival rates, fertilization rates, pregnancy rates, livebirth/transfers, and the number of live births reports for frozen and fresh oocytes.

Based upon the information provided in the published literature, the success rates reported in regards to fertilization rates, pregnancy rates, live birth/transfers and live birth rates were equivalent to or comparable to the Vit Kit® - Freeze and Vit Kit® - Thaw. Therefore, the published clinical data provided supports the substantial equivalence of the Vit Kit® - Freeze and Vit Kit® - Thaw.

Conclusion:

The results of the testing described above provide a reasonable assurance that Vit Kit® - Freeze and Vit Kit® - Thaw is as safe and effective as the predicate device and supports and determination of substantial equivalence

Regulation Number and Section

§ 884.6180 Reproductive media and supplements.

(a)
Identification. Reproductive media and supplement are products that are used for assisted reproduction procedures. Media include liquid and powder versions of various substances that come in direct physical contact with human gametes or embryos (including water, acid solutions used to treat gametes or embryos, rinsing solutions, sperm separation media, supplements, or oil used to cover the media) for the purposes of preparation, maintenance, transfer or storage. Supplements are specific reagents added to media to enhance specific properties of the media (e.g., proteins, sera, antibiotics, etc.).(b)
Classification. Class II (special controls) (mouse embryo assay information, endotoxin testing, sterilization validation, design specifications, labeling requirements, biocompatibility testing, and clinical testing). The device, when it is phosphate-buffered saline used for washing, and short-term handling and manipulation of gametes and embryos; culture oil used as an overlay for culture media containing gametes and embryos; and water for assisted reproduction applications, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 884.9.